133 related articles for article (PubMed ID: 35471043)
1. Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing
Shapiro S
Antimicrob Agents Chemother; 2022 May; 66(5):e0029822. PubMed ID: 35471043
[No Abstract] [Full Text] [Related]
2. Sigmoid
Knechtle P; Shapiro S; Morrissey I; De Piano C; Belley A
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0092621. PubMed ID: 34097479
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing
Johnson A; McEntee L; Farrington N; Kolamunnage-Dona R; Franzoni S; Vezzelli A; Massimiliano M; Knechtle P; Belley A; Dane A; Drusano G; Das S; Hope W
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253209
[No Abstract] [Full Text] [Related]
5. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
Belley A; Morrissey I; Hawser S; Kothari N; Knechtle P
J Glob Antimicrob Resist; 2021 Jun; 25():93-101. PubMed ID: 33746112
[TBL] [Abstract][Full Text] [Related]
6. Multicenter surveillance of
Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
[TBL] [Abstract][Full Text] [Related]
7. Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A
Antimicrob Agents Chemother; 2022 May; 66(5):e0035322. PubMed ID: 35471039
[No Abstract] [Full Text] [Related]
8.
Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
[TBL] [Abstract][Full Text] [Related]
9. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.
Bernhard F; Odedra R; Sordello S; Cardin R; Franzoni S; Charrier C; Belley A; Warn P; Machacek M; Knechtle P
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253212
[TBL] [Abstract][Full Text] [Related]
11. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
Isler B; Harris P; Stewart AG; Paterson DL
J Antimicrob Chemother; 2021 Feb; 76(3):550-560. PubMed ID: 33332545
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
[TBL] [Abstract][Full Text] [Related]
13. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in
Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae.
Kaku N; Kosai K; Takeda K; Uno N; Morinaga Y; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507106
[TBL] [Abstract][Full Text] [Related]
15. Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
Das S; Fitzgerald R; Ullah A; Bula M; Collins AM; Mitsi E; Reine J; Hill H; Rylance J; Ferreira DM; Tripp K; Bertasini A; Franzoni S; Massimiliano M; Lahlou O; Motta P; Barth P; Velicitat P; Knechtle P; Hope W
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077666
[TBL] [Abstract][Full Text] [Related]
16. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
17. Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728.
Saral Sariyer A
J Mol Model; 2022 Mar; 28(4):76. PubMed ID: 35243556
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
19. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
20. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
Lasko MJ; Nicolau DP; Asempa TE
J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
